- Home
- REGN vs RELX Comparison
REGN vs RELX Comparison
Compare REGN & RELX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- RELX
- Stock Information
- Founded
- REGN 1988
- RELX 1903
- Country
- REGN United States
- RELX United Kingdom
- Employees
- REGN N/A
- RELX N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- RELX Business Services
- Sector
- REGN Health Care
- RELX Consumer Discretionary
- Exchange
- REGN Nasdaq
- RELX Nasdaq
- Market Cap
- REGN 110.0B
- RELX 91.3B
- IPO Year
- REGN 1991
- RELX N/A
- Fundamental
- Price
- REGN $700.33
- RELX $49.31
- Analyst Decision
- REGN Buy
- RELX Strong Buy
- Analyst Count
- REGN 26
- RELX 1
- Target Price
- REGN $996.00
- RELX N/A
- AVG Volume (30 Days)
- REGN 905.6K
- RELX 628.5K
- Earning Date
- REGN 02-04-2025
- RELX 02-28-2025
- Dividend Yield
- REGN 0.13%
- RELX 1.13%
- EPS Growth
- REGN 10.27
- RELX 10.15
- EPS
- REGN 38.34
- RELX 1.29
- Revenue
- REGN $14,202,000,000.00
- RELX $11,810,658,884.00
- Revenue This Year
- REGN $5.20
- RELX $10.59
- Revenue Next Year
- REGN $6.39
- RELX $6.94
- P/E Ratio
- REGN $18.27
- RELX $37.75
- Revenue Growth
- REGN 8.27
- RELX 2.98
- 52 Week Low
- REGN $642.00
- RELX $40.25
- 52 Week High
- REGN $1,211.20
- RELX $51.99
- Technical
- Relative Strength Index (RSI)
- REGN 52.55
- RELX 47.05
- Support Level
- REGN $655.85
- RELX $49.94
- Resistance Level
- REGN $689.95
- RELX $51.99
- Average True Range (ATR)
- REGN 21.25
- RELX 0.52
- MACD
- REGN 2.98
- RELX -0.22
- Stochastic Oscillator
- REGN 63.22
- RELX 6.65
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.